Also, there will be a market for chemotherapy but likely not as large with further alternate cancer treatments being approved as SoC drugs before patient undergo the last treatment alternative of full chemotherapy. IMU will just maximise the HER-Vaxx asset into the T/O by BP for all their assets, PD1-Vaxx is starting Ph2 clinical trial this year so I'm not sure how you can call it a "failed B cell technology". RAC's only IP RC220 hasn't even started Ph1 clinical trial so is it a "failed" IP????
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)